SCHEMBL15034142

SCHEMBL15034142

CC(C)COc1cccc(C(=O)N2CCN(C(=O)c3ncn(-c4ccccc4)n3)C(C)(C)C2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.40
SLC16A1 P53985 1/20 0.40
FAAH O00519 1/20 0.39
CFTR P13569 1/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
KAT6A Q92794 1/20 0.37
ALDH1A1 P00352 2/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
HTT P42858 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 3/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
CRHBP P24387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034148 0.91 MEN1 (0.47) CFTRKMT2AMEN1ALDH1A1HTT
SCHEMBL15034139 0.89 ALDH1A1 (0.47) CFTRKMT2AMEN1ALDH1A1MAPT
SCHEMBL15020047 0.85 HPGD (0.41) CFTRKMT2AMEN1ALDH1A1MAPT
SCHEMBL15034134 0.85 CFTR (0.44) CFTRALDH1A1MAPTTP53POLB
SCHEMBL15034152 0.84 MAPT (0.39) CFTRKMT2AMEN1ALDH1A1MAPT
SCHEMBL15034138 0.84 HPGD (0.44) CFTRALDH1A1HTTMAPTTP53
SCHEMBL15034136 0.84 CFTR (0.40) CFTRALDH1A1MAPTTP53POLB
SCHEMBL15020006 0.83 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1HTTMAPT
SCHEMBL15034131 0.83 CYP3A4 (0.48) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
SCHEMBL15034043 0.82 MAPT (0.41) KMT2AALDH1A1ITGB3ITGA2BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 SLC16A3 2516/4885SLC16A1 1955/4885FAAH 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.